SXTP 60 DEGREES PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1946563 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.8%
TTM net income YoY-4.7%
TTM EPS YoY95.7%
Revenue 3-yr CAGR115.4%
Net income 3-yr CAGR—
Margins
Gross margin24.1%
Operating margin-971.9%
Net margin-921.0%
FCF margin-906.9%
EBITDA margin-964.6%
Returns
ROE-316.7%
ROA-170.7%
ROIC (approx.)-1,197.4%
Asset turnover0.19x
Leverage & solvency
Liabilities / assets75.6%
Debt / equity0.18x
Current ratio1.17x
Interest coverage-1,207.18x
Cash quality & payout
Operating cash flow / net income0.97x
Accruals ratio-4.8%
Payout ratio—
Capex / revenue12.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $233,235 | $207,898 | $162,092 | $303,385 | $437,602 | $100,932 | $163,552 | $230,846 |
| Cost of revenue | $330,766 | $151,100 | $85,715 | $120,682 | $537,690 | $50,051 | $73,272 | $118,077 |
| Gross profit | -$97,531 | $56,798 | $76,377 | $182,703 | -$100,088 | $50,881 | $90,280 | $112,769 |
| R&D expense | $782,595 | $598,653 | $281,464 | $638,873 | $786,465 | $231,912 | $370,813 | $613,955 |
| SG&A expense | $1.65M | $1.73M | $1.89M | $1.47M | $1.53M | $1.63M | $1.72M | $1.61M |
| Operating income | -$2.53M | -$2.27M | -$2.09M | -$1.92M | -$2.33M | -$1.61M | -$1.91M | -$2.07M |
| Interest expense | $1,421 | $1,403 | $1,389 | $3,086 | $1,708 | $1,221 | $1,790 | $1,422 |
| Pretax income | -$2.56M | -$2.27M | -$2.09M | -$1.44M | -$2.32M | -$1.73M | -$1.88M | -$2.05M |
| Income tax | — | — | — | -$1,813 | $250 | $1,500 | $63 | -$501 |
| Net income | -$2.56M | -$2.26M | -$2.09M | -$1.44M | -$2.32M | -$1.73M | -$1.88M | -$2.05M |
| EBITDA | -$2.51M | -$2.25M | -$2.08M | -$1.90M | -$2.31M | -$1.60M | -$1.90M | -$2.06M |
| EPS (basic) | -0.75 | -0.90 | -1.28 | — | -2.66 | -5.01 | -6.25 | — |
| EPS (diluted) | -0.75 | -0.90 | -1.28 | — | -2.66 | -5.01 | -6.25 | — |
| Weighted avg. shares (diluted) | 3.55M | 2.65M | 1.73M | — | 918,852 | 368,250 | 320,890 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $306,191 | $1.02M | $3.34M | $1.51M | $4.12M | $1.97M | $3.45M | $1.66M |
| Short-term investments | — | — | — | $1.24M | $0 | $0 | — | $1.73M |
| Receivables | $338,494 | $567,040 | $335,836 | $509,644 | $674,036 | $295,034 | $488,243 | $486,748 |
| Inventory | $578,524 | $877,945 | $910,603 | $656,924 | $527,004 | $799,421 | $773,238 | $442,764 |
| Current assets | $2.56M | $3.73M | $6.26M | $4.90M | $6.31M | $3.84M | $5.65M | $5.39M |
| PP&E, net | $225,815 | $242,714 | $259,665 | $246,365 | $227,752 | $193,879 | $155,792 | $149,808 |
| Intangibles | $304,031 | $308,683 | $243,212 | $224,361 | $152,383 | $143,704 | $149,785 | $157,084 |
| Total assets | $3.09M | $4.28M | $6.76M | $5.37M | $6.69M | $4.18M | $5.98M | $5.76M |
| Current liabilities | $2.19M | $1.61M | $1.88M | $1.85M | $2.20M | $1.69M | $1.80M | $1.66M |
| Short-term debt | $3,602 | $2,003 | $8,772 | $11,517 | $8,772 | $8,772 | $8,772 | $8,772 |
| Long-term debt | $150,030 | $150,030 | $150,030 | $144,003 | $150,000 | $150,000 | $150,000 | $147,119 |
| Total debt | $153,632 | $152,033 | $158,802 | $155,520 | $158,772 | $158,772 | $158,772 | $155,891 |
| Total liabilities | $2.34M | $1.75M | $2.02M | $1.99M | $2.34M | $1.84M | $1.95M | $1.80M |
| Shareholders' equity | $842,016 | $2.61M | $4.83M | $3.46M | $4.43M | $2.43M | $4.11M | $4.04M |
| Net debt | -$152,559 | -$870,573 | -$3.18M | -$1.35M | -$3.96M | -$1.81M | -$3.29M | -$1.50M |
| Shares outstanding | 1.16M | 2.66M | 2.64M | 1.16M | 4.10M | 1.47M | 1.47M | 141,749 |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.45M | -$2.23M | -$2.74M | -$1.69M | -$2.11M | -$1.45M | -$1.60M | -$1.64M |
| Capital expenditure | $0 | $0 | $30,000 | $79,881 | $9,999 | $47,323 | $2,678 | $0 |
| Free cash flow | -$1.45M | -$2.23M | -$2.77M | -$1.77M | -$2.12M | -$1.50M | -$1.60M | -$1.64M |
| Investing cash flow | -$12,648 | -$85,984 | $1.19M | -$1.37M | -$25,487 | -$51,684 | $1.70M | -$2,098 |
| Financing cash flow | $740,000 | $0 | $3.37M | $458,614 | $4.28M | $0 | $1.70M | $973 |
| Depreciation & amortization | $16,899 | $16,950 | $16,700 | $15,169 | $12,225 | $9,236 | $6,694 | $5,449 |
| Stock-based compensation | $47,802 | $98,405 | $124,102 | $111,961 | $79,000 | $78,620 | $186,763 | $61,639 |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.